Reading tubular injury by the kidney's own light

Design

preclinical study across three mouse injury models with mechanistic slice-culture work and ex vivo human tissue

Population

mouse models of ureteric obstruction, folic acid nephropathy and ischaemia-reperfusion injury, plus 34 human nephrectomy samples

Primary outcome

correlation of near-infrared autofluorescence with tubular epithelial injury, oxidative stress, fibrosis and eGFR

Effect

signal correlated with injury and fibrosis in all three models, fell with finerenone treatment, and correlated inversely with eGFR in human tissue; no correlation coefficients reported

Kidney tissue emits near-infrared autofluorescence without any injected probe, and this study asked whether that signal tracks tubular epithelial injury. It was tested across three mouse models chosen for different injury patterns - unilateral ureteric obstruction, folic acid nephropathy, and unilateral ischaemia-reperfusion - and then on 34 human samples taken from the non-cancerous part of nephrectomy specimens.

The signal correlated with tubular injury, oxidative stress markers and fibrosis in all three models. Spectroscopy pointed to coproporphyrin III as the likely fluorophore, and the mechanism held together: coproporphyrinogen oxidase was reduced in injured kidneys and lost from damaged proximal tubular cells, mice with a mutation reducing that enzyme's activity had a raised baseline signal, and in kidney slice culture a mitochondrial complex III inhibitor raised the signal while a mitochondrial reactive oxygen species scavenger reversed it. Treating obstructed and ischaemic mice with finerenone lowered the autofluorescence in step with improved histology. In the human samples the signal correlated inversely with eGFR and positively with histological injury score; no correlation coefficient is reported.

This is research-stage and should be described that way. It is not a test that exists, and the human data are ex vivo tissue rather than imaging of a living kidney. What makes it worth a nephrologist's attention is the target it points at: a non-invasive, repeatable readout of tubulointerstitial injury is the missing instrument in both trials and clinics, where the alternative is a biopsy that can only be done occasionally.

• Treat this as preclinical proof of concept - there is no clinical test to request.
• Note the human data are ex vivo nephrectomy tissue, not imaging of a living patient.
• The mechanistic chain, from enzyme loss to porphyrin accumulation to signal, is the part that makes it more than a correlation.
• Watch this as a possible trial endpoint before it becomes a clinical one - serial assessment of fibrosis is what trials currently lack.
• Nothing here changes how tubulointerstitial disease is assessed today: that remains biopsy, eGFR trajectory and albuminuria.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.